Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Aptose Biosciences Inc. (T:APS)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: 251 Consumers Rd Suite 1105
Tel: N/A
IR: See website
Key People
William Glenn Rice
Chairman of the Board, President, Chief Executive Officer, Chief Accounting Officer
Fletcher Payne
Chief Financial Officer, Senior Vice President
Rafael Bejar
Senior Vice President, Chief Medical Officer
Philippe Ledru
Chief Commercial Officer
Business Overview
Aptose Biosciences Inc. is a Canada-based clinical stage precision oncology biotechnology company. It is engaged in advancing kinase inhibitors to treat unmet medical needs in life-threatening cancers, such as acute myeloid leukemia (AML), certain B-cell malignancies, high-risk myelodysplastic syndrome (MDS) and other hematologic malignancies. Its HM43239 is being evaluated in an international Phase I/II study in patients with relapsed or refractory AML. Its Luxeptinib is being evaluated in a Phase I a/b trial in patients with relapsed or refractory B cell malignancies, and in a separate Phase I a/b trial in patients with relapsed or refractory AML or high-risk MDS. Its APTO-253 is a small molecule MYC oncogene inhibitor at the Phase Ia/b clinical trial stage of development for the treatment of patients with relapsed or refractory (R/R) blood cancers, including AML and high-risk MDS. Its APL-581 is a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program.
Financial Overview
For the fiscal year ended 31 December 2022, Aptose Biosciences Inc revenues was not reported. Net loss decreased 36% to $41.8M. Lower net loss reflects Program costs Luxeptinib decrease of 54% to $8.4M (expense), Stock-based compensation decrease of 67% to $3M (expense), Program costs APTO-253 decrease of 96% to $141K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.73 to -$0.45.
Employees: 35 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $15.94M as of Dec 31, 2022
Annual revenue (TTM): $0.00M as of Dec 31, 2022
EBITDA (TTM): -$58.39M as of Dec 31, 2022
Net annual income (TTM): -$57.48M as of Dec 31, 2022
Free cash flow (TTM): -$44.46M as of Dec 31, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 92,368,000 as of Dec 31, 2022
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization